Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates across the bottom line: GAAP EPS was -$0.30 vs. -$0.26 expected, and net loss reached $7.0M vs. $6.4M anticipated. While revenue remained at $0 as expected for this clinical-stage firm, the variance was driven by higher-than-expected R&D spending (+30% YoY). However, the July follow-on offering raising $115M gross proceeds significantly strengthens the balance sheet, extending the cash runway into 1H 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nuvectis Pharma(NVCT) the Revenue is 0 (--%), Meet estimate;the EBIT is -7.197 M (-9.13%), Miss estimate;the EPS is -0.3 (+0%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITMiss expectations
-0.01B9.13%
-0.01B1.57%
-0.00B10.70%
EPSMiss expectations
-0.3--
-0.26212.67%
-0.038012.67%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf